FREE Account Opening + No Clearing Fees
Loading...
Suven Life Sciences Rights Issue 2022 Detail
Issue Open October 31, 2022
Issue Close November 10, 2022
Issue Size (Shares) 7.27 Crores
Issue Size (Amount) ₹399.80 Crores
Issue Price ₹55 per Share
Listing At BSE, NSE

Suven Life Sciences Rights Issue 2022 Date & Price FAQs

Suven Life Sciences Rights Issue 2022 Timetable

Last Date for credit of Rights EntitlementsOctober 28, 2022
Last Date for renunciation of Rights EntitlementsNovember 3, 2022
Issue Opening DateOctober 31, 2022
Issue Closing DateNovember 10, 2022
Allotment DateNovember 18, 2022
Shares Credit DateNovember 21, 2022
Listing DateNovember 24, 2022

Suven Life Sciences Rights Issue 2022 price is set at ₹55 per Share. The Suven Life Sciences Rights Issue 2022 opens on October 31, 2022, and closes on November 10, 2022, for the subscription.

The allotment of Suven Life Sciences Rights Issue 2022 is expected to happen on or about November 18, 2022 as per the issue schedule.

Suven Life Sciences Rights Issue 2022 listing date is November 24, 2022.

The credit of Suven Life Sciences Rights Issue 2022 in Demat account is expected on or about November 21, 2022 as per the issue schedule.

The Company intends to utilize the Net Proceeds from the Issue towards the funding of the following objects:

1. Meeting costs related to pharmaceutical research & development and clinical trial for molecules in the research pipelines.

2. Repayment of an inter-corporate deposit availed by the Company.

3. General corporate purposes.

It is difficult to say at what price Suven Life Sciences Rights Issue 2022 shares will list. The price depends on the demand and supply of company's shares on the day of listing.

Sorry, we do not provide rights issue's recommendations. But we share a lot of information about Suven Life Sciences Rights Issue 2022 which could help you with questions like Suven Life Sciences Rights Issue 2022 buy or not? Consider reading Suven Life Sciences Rights Issue 2022 reviews and analysis from experts posted on rights issue detail page.